Kornimate/medical-research-clean huggingface dataset:
central auditory processing and the use of hearing aids

Conditions: Auditory Processing Disorder, Central

Summary: the purpose of this study is to evaluate the central auditory processing in patients with bilateral sensorineural hearing loss and to observe the change of the central auditory processing ability after using hearing aids.

screening for recruiting * among patients who are visiting for hearing disturbance, patients with bilateral sensorineural hearing loss will be included after audiologic tests, history taking and physical examination. * audiologic tests: pure tone audiometry, speech audiometry, impedence audiometry, distortion product otoacoustic emission, auditory brainstem response. dividing into "hearing aids" group and "no hearing aids" group * the use of hearing aids will be recommended to all included patients. * hearing aids group: patients who want to be prescribed hearing aids (28 subjects) * no hearing aids group: patients who do not want to be prescribed hearing aids (28 subjects) audiologic test * hearing in noise test (hint), central auditory processing disorder test * at screening, 1, 3, 6, 9 and 12 months after starting hearing aids use

Eligibility criteria:
inclusion criteria: * adults of age 45 years of older * bilateral sensorineural hearing loss * average pure tone audiometry threshold \>= 40db * speech discrimination \>= 60% in both ears exclusion criteria: * refusing the study * medical history of any brain damage or intracranial surgery * showing signs of central lesion in mri or neurologic exams * speech discrimination \< 60% in any ear

Keywords: central auditory processing bilateral sensorineural hearing loss hearing aids
headstrong intervention for pediatric headache

Conditions: Chronic Headaches

Summary: purpose of this study is to determine if a cd-rom computer program (called "headstrong") is effective in helping children cope with chronic headaches.

children, 7-12 years, with recurrent headaches are randomly assigned to an educational cd-rom program or the headstrong cd-rom program. we anticipate that those assigned to the active (headstrong) program group will have significantly greater reductions in headache frequency, duration, and severity and improvements in mood and quality of life.

Eligibility criteria:
inclusion criteria: * 7-12 years of age * having recurrent, intermittent, nonmalignant headaches occurring on an average of at least once per week by parental or child report and separated by symptom-free periods * having a diagnosis by a nurse practitioner, pediatrician, or pediatric neurologist of migraine, muscle-contraction, or chronic daily headaches exclusion criteria: * their medical history and/or neurological exam suggests that headaches are secondary to another physical or developmental condition * their parents report they have been diagnosed with a mental health condition or they are receiving concurrent psychotherapy * their baseline headache diaries indicate an average headache frequency of less than one per week

Keywords: migraine tension headaches chronic daily headaches
adenosine-induced stress dynamic myocardial perfusion imaging with dual-source ct

Conditions: Coronary Artery Disease

Summary: this study was designed as a prospective multicenter trial to determine the accuracy of combined ct coronary angiography and perfusion imaging, specifically quantitative dynamic perfusion imaging in patients with suspicious coronary artery disease compared conventional coronary angiography and quantitative dynamic perfusion mri as standard reference.


Eligibility criteria:
inclusion criteria: 1. men and women patients, with age ranging 40-80. 2. suspected coronary artery disease who are supposed to undergo invasive coronary angiography with appropriate clinical indications 3. patients who are willing to sign the informed consent form exclusion criteria: 1. contraindication of ct known allergy to iodinated contrast media or history of contrast-induced nephropathy decreased renal function: elevated serum creatinine(\>1.5mg/dl) contraindication to beta-blockers severe arrhythmia: arterial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block) 2. contraindication of mri claustrophobia metallic hazards pacemaker implant egfr\<30 ml/min 3. unstable or uncooperative patients 4. limited life expectancy due to cancer or end-stage renal or liver disease 5. evidence of severe symptomatic heart failure (nyha class iii or iv) 6. previous myocardial infarction, coronary artery intervention, coronary artery bypass surgery, or other cardiac surgery
observational study to assess genotypes/phenotypes correlations in type-2 diabetic retinopathy

Conditions: Type-2 Diabetic Retinopathy

Summary: the purpose of this study is to characterize type 2 diabetic patients with initial alterations of diabetic retinopathy (dr) based on 3 different phenotypes previously identified and different patterns of progression in order to correlate this data with genetic information.

this study aims to to characterize type 2 diabetic patients with initial alterations of diabetic retinopathy (dr) based on three different phenotypes previously identified and different patterns of progression \[lobo, 2004\] in order to correlate this data with genetic information (based on a list of candidate genes previously identified as being involved in dr). the results of this study will be used exclusively for scientific purposes.

Eligibility criteria:
inclusion criteria: * type-2 diabetic subjects form the ptdc/sau-osm/72635/2006 clinical trial (early stages of non-proliferative retinopathy - level 30 to 35 etdrs;. females or males; age over 18 years) with a signed informed consent for this study. exclusion criteria: * cataract or other eye disease that may interfere with fundus examinations; vitreous syneresis or posterior vitreous detachment; and dilatation of the pupil \< 5 mm.
dtap and apnea/bradycardia in preterm infants

Conditions: Prolonged Apnea; Prolonged Bradycardia

Summary: the purpose of this study is to examine the relationship between receipt of dtap and the occurrence of prolonged episodes of apnea and bradycardia in preterm infants, while employing a random control study design and an objective assessment of cardiorespiratory events.

the american academy of pediatrics (aap) recommends the immunization of preterm infants at two months chronological age with the diphtheria-tetanus-acellular pertussis (dtap) vaccine, regardless of birth weight and gestational age. however, several investigators, employing historical controls and subjective observations, have reported an increased incidence in prolonged apnea and bradycardia in preterm infants following immunization. consequently, many primary care providers do not adhere to recommended aap guidelines. the purpose of this study is to reexamine the relationship between receipt of dtap and the occurrence of prolonged episodes of apnea and bradycardia in preterm infants, while employing a random control study design and an objective assessment of cardiorespiratory events. ten participating hospitals will enroll infants \ 15 sec in duration if associated with bradycardia for ≥5 sec) and prolonged bradycardia (heart rate \<80 bpm that lasted ≥10 sec) in all infants. the presence and number of episodes during the 48-hour period will be compared between the 2 groups.

Eligibility criteria:
inclusion criteria: * born at a gestational age \< 37 weeks. * still in the hospital at time of study. * between 56 - 60 days chronological age. exclusion criteria: * had active infections, were critically ill, or had unstable vital signs. * requiring assisted ventilation or tracheostomy during the study.

Keywords: apnea bradycardia preterm infant immunization dtap
the value of mri in assessing the status of retroperitoneal resection margin in colon cancer

Conditions: Colon Cancer

Summary: the goal of this clinical trial is to explore the value of colon mri in assessing the status of retroperitoneal resection margin (rprm) for advanced colon cancer. the main questions it aims to answer are: * concordance between mri suspected rprm positive and pathologically confirmed positive. * can rprm-positive patients undergo beyond complete mesocolic excision (cme) surgery in order to achieve r0 resection? participants will undergo colon mri examination and once mri suspects rprm positive, they will receive beyond cme surgery.


Eligibility criteria:
inclusion criteria: * primary colon adenocarcinoma confirmed by biopsy * preoperative ct suspecting retroperitoneal resection margin (rprm) positive * received colon mri scan * underwent beyond complete mesocolic excision surgery * sufficient clinical and pathological results exclusion criteria: * combined with other malignant tumors * simultaneous distant metastasis * definite invaded other organs or structures (t4b tumors)

Keywords: colon cancer mri resection margin
percutaneous repair of acute achilles tendon rupture with assistance of intraoperative ultrasound

Conditions: Acute Rupture of Achilles Tendon

Summary: this is a prospective randomized controlled study carried out between may 2016 and december 2020. it included 98 patients presented with acute rupture of achilles tendon the patients were randomly distributed by closed envelop technique (49 in each group). group a included those managed with the assistant of an intra-operative ultrasound. group b included those done without ultrasound assistant

a preoperative prophylactic dose of antibiotic was given intravenously in the form of 2gm of cephalosporin one hour before operation. under general or regional anesthesia, the patient laid in prone position without a tourniquet and both feet out of the table for easily mobilization of the ankle joint. in group a, an intraoperative ultrasound was done by a radiologist before the repair for identification the course of sural nerve and outline the medial and lateral edges of torn tendon. then ultrasound was repeated after repair for confirmation of adequate contact of both stumps and satisfactory strength of the repair by visualization of the tendon with passive motion of the ankle. for patients in group b, the course of the sural nerve was determined according to the technique described by blackmon et al. this technique depends on the leg length for location the point where the nerve crosses the lateral edge of the tendon. the medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. the technique of repair was standardized for all patients in both groups. we used the technique described by maffulli et al

Eligibility criteria:
inclusion criteria: * age between 18 and 50 years * acute ( not more than two weeks) closed complete injury * injury of achilles tendon in zone 2 (the area between 3 and 6 cm from the insertion) according to langergran and lindholm exclusion criteria: * incomplete injury * recurrent injury * associated fracture ankle or foot * previous history of local corticosteroids injection * patients with neurovascular problem (e.g. diabetic, autoimmune ...etc), smoking, and alcoholics
a study to assess the efficacy and safety of asp1941 in combination with pioglitazone in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: this study is to evaluate the efficacy and safety after concomitant administration of asp1941 and pioglitazone in patients with diabetes mellitus.

this study is to evaluate the efficacy (hba1c change from baseline) and safety of asp1941 in combination with pioglitazone in subjects with type 2 diabetes mellitus (t2dm) who have inadequate glycemic control with pioglitazone alone. the effects of asp1941 are compared with those of placebo. double blind period continues for 24 weeks followed by open period in each patient.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients receiving pioglitazone mono-therapy for at least 4 weeks * hba1c value between 7.0 and 9.5% * body mass index (bmi) 20.0 - 45.0 kg/m2 exclusion criteria: * type 1 diabetes mellitus patients * serum creatinine \> upper limit of normal * proteinuria (albumin/creatinine ratio \> 300mg/g) * dysuria and/or urinary tract infection, genital infection * significant renal, hepatic or cardiovascular diseases * severe gastrointestinal diseases * heart failure patients

Keywords: asp1941 diabetes mellitus pioglitazone
imaging the duodenum using an optical frequency domain imaging ofdi capsule

Conditions: Celiac Disease; Healthy

Summary: the study is being done to assess the tolerability and feasibility of a tethered ofdi capsule to image the duodenum. a total of 24 subjects will be asked to swallow the tethered capsule, while they are awake and unsedated and ask for their feedback. images will be taken using the ofdi system while the capsule travels from the esophagus into the stomach and into the duodenum.

subjects including healthy volunteers as well as patients with celiac disease will be recruited and asked to swallow the ofdi capsule while being awake and unsedated. the capsule is attached to a tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus, through the stomach and into the duodenum using natural propulsive force called peristalsis. as the capsule progresses, multiple 2-dimensional cross sectional images of the duodenum are acquired. images are analyzed at a later stage.

Eligibility criteria:
inclusion criteria: * subject must be over 18 years for healthy volunteers * subjects must be over 16 years for patients with celiac disease * subject must be able to give informed consent exclusion criteria: * subjects with an inability to swallow pills or capsules. * subjects with esophageal or intestinal fistulas. * subjects with known esophageal or intestinal strictures resulting in a luminal diameter smaller than the diameter of the capsule. * subjects with a history of intestinal crohn's disease. * women who are pregnant.

Keywords: duodenum optical frequency domain imaging (ofdi) optical coherence tomography imaging celiac disease
institutional registry of haemorrhagic hereditary telangiectasia

Conditions: Haemorrhagic Hereditary Telangiectasia

Summary: the purpose of this study is to create an institutional and population-based registry of haemorrhagic hereditary telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival. this study will also describe the occurrence of haemorrhagic hereditary telangiectasia in the population of hiba in the central hospital, as well as the characteristics of clinical presentation and evolution.

haemorrhagic hereditary telangiectasia is a uncommon autosomic hereditary disorder caracterizad for recurrent epistaxis,cutaneomucous telangiectasias and arteriovenous malformations in diferent organs; brain, lung, liver and gastrointestinal are more often afected . afect one in 5000-8000 individual in worldwide. hht may produce important morbidity like brain absces, stroke, hemoptisis and cronic ferropenic anemia. molecular mechanism of this disorder are complex and still no fully dilucidated. the genes mutated in hht encode endothelial cell-expressed proteins that mediate signalling by the transforming growth factor (tgf)b superfamily. endoglin (hht type i) and acvrl-1 (hht type 2) mutations are responsible in more than 80% of the individuals. mutation of smad 4 protein (madh4)cause hht in association with juvenile polyposis. hht may associated with primary pulmonary hypertension en more rare cases. there are not hht registry in argentina and latinamerican population. this registry may gader valious information in order to generate a better diagnosis and treatment of our population and others.

Eligibility criteria:
inclusion criteria: 1. patients with hht defined. 2. followed in unidad hht of hospital italiano de buenos aires. exclusion criteria: 1. denied to participated in the registry or inform consent process.

Keywords: haemorrhagic hereditary telangiectasia rendu osler weber syndrome osler weber rendu syndrome hht
effect of jianpi huatan decoction on advanced colorectal cancer

Conditions: Colorectal Neoplasms

Summary: this study will take progression-free survival and overall survival as the main evaluation indexes, to evaluate the efficacy of jianpi huatan decoction in the treatment of advanced colorectal cancer. decision trees and discriminant analysis will be used to analyze the characteristics of dominant population combined with clinical data of patients. dna methylation of the subjects will be detected to study the methylation characteristics of the preponderant population of jianpi huatan decoction.


Eligibility criteria:
inclusion criteria: 1. patients with colorectal cancer with clear pathological diagnosis and western medicine diagnostic criteria. 2. tnm classification of stage iv disease according to national comprehensive cancer network (nccn) guidelines. 3. expected survival time is over 3 months. 4. the age of 18 years old or more. 5. according to the efficacy evaluation criteria for solid tumors (recist 1.1), there are measurable lesions. 6. chemotherapy and/or targeted therapy are planned. 7. signed informed consent. exclusion criteria: 1. history of previous or combined malignancies except non-melanoma skin cancer, cervical cancer in situ, or bladder cancer (tis and t1) received adequate treatment in the five years prior to screening. 2. combined with severe heart, liver, lung and kidney disease. 3. patients have intestinal obstruction can't take decoction and need intravenous high-energy nutrition. patients have malabsorption syndrome or other disease affecting gastrointestinal absorption or have active peptic ulcer disease. 4. any unstable condition or condition that may endanger patient safety and compliance with research, such as pregnancy, depression, manic-depressive disorder, obsessive-compulsive disorder, or schizophrenia. 5. the expected survival time is less than 3 months. 6. the researchers determine that they were not suitable for the study.

Keywords: colorectal cancer traditional chinese medicine
mindfulness on physical and mental condition in older adults with chronic pain

Conditions: Chronic Pain

Summary: this research corresponds to an experimental study, a randomized controlled clinical trial in people over 65 years of age, distributed into two groups: the experimental group will receive a program that will consist of an eight-week mindfulness-based intervention; and the control group that will only receive general recommendations about the benefits of physical exercise. measurements will be carried out at the beginning of the intervention and immediately after its completion.


Eligibility criteria:
inclusion criteria: * the study participants are men and women over 65 years of age residing in the city of jaén (spain). * people with pain with more than 3 months of evolution. * participants must have completed the informed consent. exclusion criteria: * that they do not voluntarily accept to participate in the study and that they are able to understand the instructions and follow the instructions of the intervention.
bioequivalency study of 600 mg oxcarbazepine tablets under fasting conditions

Conditions: Seizures; Epilepsy

Summary: the objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation compared with novartis pharmaceutical's 600 mg oxcarbazepine tablet, trileptal, following a single 600 mg dose administered under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on the physical examination, medical history, or clinical labratory results duirng screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to oxcarbazepne or any other comparable or similar product.
a study comparing sb2 to remicade® in subjects with moderate to severe rheumatoid arthritis despite methotrexate therapy

Conditions: Rheumatoid Arthritis

Summary: this is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of sb2 compared to remicade in subjects with moderate to severe rheumatoid arthritis (ra) despite methotrexate (mtx) therapy.


Eligibility criteria:
inclusion criteria: * diagnosed as having ra according to the revised 1987 acr criteria for at least 6 months * have moderate to severe active disease despite mtx therapy defined as having more than or equal to six swollen joints and more than or equal to six tender joints and either erythrocyte sedimentation rate (esr, westergren) ≥ 28 mm/h or serum c-reactive protein ≥ 1.0 mg/dl * must have been treated with mtx for at least 6 months prior to randomisation and on a stable dose of mtx 10-25 mg/week given at least 4 weeks prior to screening * female subjects who are not pregnant or nursing at screening and who are not planning to become pregnant from screening until 6 months after the last dose of investigational product inclusion criteria for transition-extension period: * have been enrolled and completed the scheduled week 54 visit of the randomised, double-blind period of the sb2-g31-ra study * in the opinion of the investigator, subjects who may benefit from continuing ip treatment (either sb2 or remicade), understand the implications of taking part in the study and willing to participate in the transition-extension period exclusion criteria: * have been treated previously with any biological agents including any tumour necrosis factor inhibitor * have a known hypersensitivity to human immunoglobulin proteins or other components of remicade or sb2 * have a positive serological test for hepatitis b or hepatitis c or have a known history of infection with human immunodeficiency virus * have a current diagnosis of active tuberculosis * have had a serious infection or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to randomisation. * have any of the following conditions 1. other inflammatory or rheumatic diseases. 2. history of any malignancy within the previous 5 years prior to screening 3. history of lymphoproliferative disease including lymphoma. 4. history of congestive heart failure 5. physical incapacitation (acr functional class iv or wheelchair-/bed-bound). 6. history of demyelinating disorders. exclusion criteria for transition-extension period: * have been withdrawn from the sb2-g31-ra study for any reason * have had any significant medical conditions, such as an occurrence of a serious ae (sae) or intolerance of sb2 or remicade during the randomised, double-blind period of the sb2-g31-ra study which may render the subject unsuitable to participate in the transition-extension period, at the discretion of the investigator

Keywords: rheumatoid arthritis infliximab biosimilar